Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Leerink Partners Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $2

Author: Benzinga Newsdesk | October 17, 2025 07:47am
Leerink Partners analyst Roanna Ruiz initiates coverage on iBio (NASDAQ:IBIO) with a Outperform rating and announces Price Target of $2.

Posted In: IBIO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist